Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




DiagnoCure Acquires Samba Technologies

By HospiMedica staff writers
Posted on 08 Jan 2004
In a move to insure its future growth, DiagnoCure (Quebec City, Canada) has acquired the assets, customer lists, and intellectual property of Samba Technologies SARL (France). More...


The intellectual property includes digital imaging and information technology that will help DiagnoCure create new applications in cancer diagnostic immunoassays. Digital imaging is necessary for the automation of immunopathology assays, a requirement for clinical laboratories performing large-volume testing. Prior to the acquisition, Samba had been a partner with DiagnoCure in the automation of its bladder cancer immunoassay, ImmunCyt/uCyt+. Samba's products are currently found in cancer centers and pathology reference laboratories throughout Europe and North America.

No financial details were disclosed. In November 2003, DiagnoCure gave an exclusive worldwide license to Gen-Probe to use its PCA3 (DD3) technology in prostate cancer.

DiagnoCure specializes in the development, production, and commercialization of diagnostic tests for detecting cancer. Currently, the company is actively pursuing the development of a prototype test for lung cancer detection.




Related Links:
DiagnoCure
Samba

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.